Skip to main content

Advertisement

Table 2 Demographic, genetic, and biochemical data in the individual subcohorts

From: Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations

  Total cohort (n = 716) Cohort 1a (n = 138) Cohort 1b (n = 72) Cohort 2 (n = 81) Cohort 3 (n = 121) Cohort 4 (n = 39) Cohort 5 (n = 37) Cohort 6 (n = 48) Cohort 7 (n = 58) Cohort 8 (n = 24) Cohort 9 (n = 44) Cohort 10 (n = 54)
Location   Gothenburg, Sweden Gothenburg, Sweden Perugia, Italy Stockholm, Sweden Malmö, Sweden Malmö, Sweden Mölndal, Sweden Kuopio, Finland Munich, Germany Stockholm, Sweden Mölndal, Sweden
Type of clinic   Affective disorders clinic Affective disorders clinic Memory clinic Memory clinic Memory clinic Memory clinic Memory clinic Memory clinic Memory clinic Memory clinic Memory clinic
Diagnosis   Bipolar disorder Controls Controls Controls Controls Controls Controls Controls Controls Controls Controls
Age (years), mean (range) 53.3 (17–99) 39.4 (20–73) 37.9 (21–74) 53.0 (21–88) 68.0 (40–92) 72.4 (60–87) 62.9 (42–99) 66.6 (52–80) 65.6 (45–81) 63.0 (49–84) 60.9 (23–88) 22.0 (17–34)
Male, n (%) 305 (42.6) 55 (39.9) 27 (37.5) 22 (27.2) 36 (29.8) 15 (38.5) 16 (43.2) 22 (45.8) 30 (51.7) 15 (62.5) 19 (43.2) 48 (88.9)
Female, n (%) 411 (57.4) 83 (60.1) 45 (62.5) 59 (72.8) 85 (70.2) 24 (61.5) 21 (56.8) 26 (54.2) 28 (48.3) 9 (37.5) 25 (56.8) 6 (11.1)
APOE ε4–/–, n (%) 506 (70.7) 93 (67.4) 49 (68.1) 65 (80.2) 88 (72.7) 29 (74.4) 25 (67.6) 32 (66.7) 40 (69.0) 19 (79.2) 31 (70.5) 35 (64.8)
APOE ε4+/–, n (%) 190 (26.5) 41 (29.7) 20 (27.8) 14 (17.3) 32 (26.4) 10 (25.6) 10 (27.0) 15 (31.3) 16 (27.6) 5 (20.8) 11 (25.0) 16 (29.6)
APOE ε4+/+, n (%) 20 (2.8) 4 (2.9) 3 (4.2) 2 (2.5) 1 (0.8) 0 (0.0) 2 (5.4) 1 (2.1) 2 (3.4) 0 (0.0) 2 (4.5) 3 (5.6)
CSF Aβ42 assay and concentrations measured (ng/L), mean (SD)   xMAP Luminex AlzBio3 xMAP Luminex AlzBio3 INNOTEST β-amyloid[1–42] INNOTEST β-amyloid[1–42] INNOTEST β-amyloid[1–42] xMAP Luminex AlzBio3 INNOTEST β-amyloid[1–42] INNOTEST β-amyloid[1–42] INNOTEST β-amyloid[1–42] INNOTEST β-amyloid[1–42] INNOTEST β-amyloid[1–42]
 All genotypes 252.1 (71.0) 257.7 (57.7) 255.1 (54.2) 260.2 (91.5) 250.8 (75.8) 260.3 (67.6) 245.4 (58.7) 250.3 (39.8) 242.2 (71.9) 247.6 (72.3) 259.0 (92.4) 232.1 (84.6)
APOE ε4–/– 261.2 (70.9) 264.6 (57.2) 259.8 (51.7) 262.5 (93.9) 264.0 (68.2) 260.8 (66.0) 257.5 (66.2) 258.3 (36.8) 258.5 (75.0) 260.9 (72.9) 276.6 (89.1) 240.6 (93.0)
APOE ε4+/– 234.8 (65.4) 250.5 (51.4) 245.3 (63.1) 266.4 (76.0) 219.7 (82.5) 258.9 (75.7) 220.3 (29.0) 241.7 (31.4) 205.4 (52.2) 197.0 (46.3) 230.0 (90.4) 216.0 (66.6)
APOE ε4+/+ 185.5 (59.0) 172.0 (67.9) 243.3 (21.1) 139.3 (24.6) 87.5 (N/A) N/A 219.2 (13.4) 125.7 (N/A) 209.7 (10.0) N/A 143.9 (31.5) 218.0 (75.1)
  1. APOE apolipoprotein E, Aβ42 beta-amyloid1–42, CSF cerebrospinal fluid, SD standard deviation, N/A not available